NZ761478B2 - Antagonist antibodies directed against calcitonin gene-related peptide and methods using same - Google Patents
Antagonist antibodies directed against calcitonin gene-related peptide and methods using sameInfo
- Publication number
- NZ761478B2 NZ761478B2 NZ761478A NZ76147815A NZ761478B2 NZ 761478 B2 NZ761478 B2 NZ 761478B2 NZ 761478 A NZ761478 A NZ 761478A NZ 76147815 A NZ76147815 A NZ 76147815A NZ 761478 B2 NZ761478 B2 NZ 761478B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- monoclonal antibody
- subject
- cdr
- seq
- formulated
- Prior art date
Links
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 title claims abstract 6
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 title claims 5
- 239000005557 antagonist Substances 0.000 title 1
- 206010027599 migraine Diseases 0.000 claims abstract 8
- 208000019695 Migraine disease Diseases 0.000 claims abstract 7
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 206010019233 Headaches Diseases 0.000 claims 4
- 231100000869 headache Toxicity 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 210000001015 abdomen Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical group CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 claims 2
- 210000000689 upper leg Anatomy 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000001667 episodic effect Effects 0.000 claims 1
- 229960003133 ergot alkaloid Drugs 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 239000003521 serotonin 5-HT1 receptor agonist Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 229940127597 CGRP antagonist Drugs 0.000 abstract 1
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 abstract 1
- 239000003735 calcitonin gene related peptide receptor antagonist Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
The invention features methods for preventing or treating CGRP associated disorders, in particular migraine headache by administering an anti-CGRP antagonist antibody at a dose of 675mg once every three months.
Claims (21)
1. Use of a monoclonal antibody that inhibits the calcitonin gene-related peptide (CGRP) pathway in the manufacture of a medicament for treating or reducing the incidence of migraine headache in a subject, 5 wherein the monoclonal antibody is formulated to be administered at a dose of about 675 mg once every three months, and wherein the monoclonal antibody comprises a CDR H1 as set forth in SEQ ID NO: 3; a CDR H2 as set forth in SEQ ID NO: 4; a CDR H3 as set forth in SEQ ID NO: 5; a CDR L1 as set forth in SEQ ID NO: 6; a 10 CDR L2 as set forth in SEQ ID NO: 7; and a CDR L3 as set forth in SEQ ID NO: 8.
2. The use of claim 1, wherein the migraine headache is chronic migraine headache.
3. The use of claim 1, wherein the migraine headache is episodic 15 migraine headache.
4. The use of any one of claims 1 to 3, wherein the incidence of migraine headache is reduced for at least seven days after a single administration.
5. The use of any one of claims 1 to 4, wherein monthly headache 20 hours experienced by the subject after said administering is reduced by 40 or more hours from a pre-administration level in the subject.
6. The use of any one of claims 1 to 5, wherein monthly headache days experienced by the subject after said administering is reduced by 3 or more days from a pre-administration level in the subject. 25
7. The use of any one of claims 1 to 6, wherein monthly headache hours experienced by the subject after said administering is reduced by 25% or more relative to a pre-administration level in the subject.
8. The use of any one of claims 1 to 7, wherein the monoclonal antibody is formulated for subcutaneous administration. 161
9. The use of any one of claims 1 to 7, wherein the monoclonal antibody is formulated for intravenous administration.
10. The use of any one of claims 1 to 9, wherein the monoclonal antibody is formulated to be administered by utilizing a pre-filled 5 syringe comprising the amount of the monoclonal antibody.
11. The use of any one of claims 1 to 10, wherein the monoclonal antibody is formulated at a concentration of at least 150 mg/mL.
12. The use of any one of claims 1 to 11, wherein the monoclonal antibody is formulated to be administered in a volume of less than 2 10 mL.
13. The use of any one of claims 1 to 12, wherein the dose of 675 mg of the monoclonal antibody is formulated to be administered as three injections of 225 mg each.
14. The use of claim 13, wherein each 225mg injection is 1.5 mL.
15 15. The use of any one of claims 1 to 14, wherein the medicament further comprises a second agent formulated to be administered simultaneously or sequentially with the monoclonal antibody to the subject or wherein the monoclonal antibody is formulated to be administered simultaneously or sequentially with a second agent to 20 the subject.
16. The use of claim 15, wherein the second agent is selected from the group consisting of: 5-HT1 agonists, triptans, ergot alkaloids, and non-steroidal anti-inflammatory drugs.
17. The use of claim 15 or claim 16, wherein use of the second agent by 25 the subject is decreased by at least 15% after administering the monoclonal antibody.
18. The use of any one of claims 15 to 17, wherein the second agent is a triptan. 162
19. The use of any one of claims 1 to 18, wherein the monoclonal antibody is human or humanized.
20. The use of any one of claims 1 to 19, wherein the monoclonal 5 antibody is formulated to be administered via injections into the abdomen, thigh, or upper arm of the subject’s body.
21. Use of a monoclonal antibody that inhibits the calcitonin gene-related peptide (CGRP) pathway in the manufacture of a medicament for treating or reducing the incidence of migraine headache in a subject, 10 wherein the monoclonal antibody is formulated to be administered at a dose of 675 mg once every three months, wherein the monoclonal antibody comprises (a) an antibody having a CDR H1 as set forth in SEQ ID NO: 3; a CDR H2 as set forth in SEQ ID NO: 4; a CDR H3 as set forth in SEQ ID NO: 5; a CDR L1 as set forth in SEQ ID NO: 15 6; a CDR L2 as set forth in SEQ ID NO: 7; and a CDR L3 as set forth in SEQ ID NO: 8; and wherein the 675 mg dose is formulated to be administered as three consecutive 225 mg subcutaneous injections of 1.5 mL to the abdomen, thigh, or upper arm of the subject’s body
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461968897P | 2014-03-21 | 2014-03-21 | |
| US201462083809P | 2014-11-24 | 2014-11-24 | |
| US201562119778P | 2015-02-23 | 2015-02-23 | |
| NZ724442A NZ724442B2 (en) | 2014-03-21 | 2015-03-20 | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ761478A NZ761478A (en) | 2024-01-26 |
| NZ761478B2 true NZ761478B2 (en) | 2024-04-30 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Malone et al. | The immune system and stroke: from current targets to future therapy | |
| JP2017510579A5 (en) | ||
| FI3227675T3 (en) | Activin-actrii antagonists and uses for treating myelodysplastic syndrome | |
| JP2012067116A5 (en) | ||
| RU2008138381A (en) | ADRENALINE DOSAGE MODES | |
| JP2015525798A5 (en) | ||
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| FI3356386T3 (en) | Method of treating melanocortin-4 receptor pathway-associated disorders | |
| RU2015152860A (en) | INTRODUCTION MODE AND COMPOSITIONS FOR TYPE B Adenoviruses | |
| RU2014101207A (en) | NEW INDICATIONS FOR USE IN TREATMENT BY ANTIBODIES AGAINST IL-1-BETA | |
| RU2012108108A (en) | CONCENTRATED POLYPEPTIDE MEDICINAL FORMS WITH REDUCED VISCOSITY | |
| JP2020512978A5 (en) | ||
| RU2009118962A (en) | APPLICATION OF IL-1 ANTAGONISTS FOR TREATMENT OF GHIT AND PSEUDOGRAPHY | |
| JP2019218359A (en) | Preparations and methods for treating gd2 positive cancer | |
| JP2016526531A5 (en) | ||
| US20100330093A1 (en) | Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4) | |
| JP2019508433A5 (en) | ||
| CN108697801A (en) | Use the combination treatment of LIV1-ADC and chemotherapy | |
| US20200069680A1 (en) | Oxabicycloheptanes for modulation of immune response | |
| IL292706A (en) | Type i interferon inhibition in systemic lupus erythematosus | |
| WO2023178019A1 (en) | Combination therapies for breast cancer | |
| WO2017176565A1 (en) | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor | |
| NZ761478B2 (en) | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same | |
| IL161665A (en) | Use of thymosin alpha 1 peptide in the manufacture of a pharmaceutical composition | |
| JP2005529152A5 (en) |